Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP & Chief Scientific Officer | July 14, 2023 | July 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 14, 2023 · Filed July 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,968 |
Reported balance
After 2023-07-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-14 · Grant · Acquired 8,056 · Balance 58,968 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Dashyant Dhanak's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including the July 14, 2023 RSU Grant, this includes an aggregate of 53,279 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.76 · Expires 2033-07-13 | Direct | 16,896 |
Reported balance
After 2023-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-14 · Grant · Acquired 16,896 · Balance 16,896 F3: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Dashyant Dhanak's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including the July 14, 2023 RSU Grant, this includes an aggregate of 53,279 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
F3: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Deciphera Pharmaceuticals, Inc.
Report date June 11, 2024 · Filed June 11, 2024
Section 16 reporting ended · disclosed 2024-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-11 · Grant · Acquired 25,913 · Balance 184,088 F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. Row 2 · 2024-06-11 · Disposition to issuer · Disposed 184,088 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.42 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-11 · Disposition to issuer · Disposed 65,900 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.92 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-11 · Disposition to issuer · Disposed 69,100 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred.
F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2020 Filed Oct 8, 2020 20:21 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 961 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-20-054279 · doc4.xml · derivative · entry 3 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,681 Underlying: Common Stock · 961 shares Expires 2028-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 20:21 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 961 | $91.97 | $88,383.17 |
DisclosureSEC source: 0001209191-20-054279 · doc4.xml · nonDerivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,010 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 22,052 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 20:21 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 961 | $65.42 | $62,868.62 |
DisclosureSEC source: 0001209191-20-054279 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:21 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 961 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-20-049959 · doc4.xml · derivative · entry 3 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,642 Underlying: Common Stock · 961 shares Expires 2028-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:21 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 961 | $88.94 | $85,471.34 |
DisclosureSEC source: 0001209191-20-049959 · doc4.xml · nonDerivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,010 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 22,052 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:21 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 961 | $65.42 | $62,868.62 |
DisclosureSEC source: 0001209191-20-049959 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 961 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-20-045938 · doc4.xml · derivative · entry 3 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,603 Underlying: Common Stock · 961 shares Expires 2028-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:20 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 961 | $97.80 | $93,985.80 |
DisclosureSEC source: 0001209191-20-045938 · doc4.xml · nonDerivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,010 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 22,052 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 961 | $65.42 | $62,868.62 |
DisclosureSEC source: 0001209191-20-045938 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:31 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,419 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-20-042366 · doc4.xml · derivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,419 shares Expires 2028-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:31 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 2,419 | $65.42 | $158,250.98 |
DisclosureSEC source: 0001209191-20-042366 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This includes an aggregate of 22,052 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:13 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 961 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-20-041549 · doc4.xml · derivative · entry 6 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,564 Underlying: Common Stock · 961 shares Expires 2028-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:13 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 961 | $106.58 | $102,423.38 |
DisclosureSEC source: 0001209191-20-041549 · doc4.xml · nonDerivative · entry 4 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,591 F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · balance_after: Including the July 2, 2020 Restricted Stock Unit Grant, this includes an aggregate of 22,052 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:13 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 961 | $65.42 | $62,868.62 |
DisclosureSEC source: 0001209191-20-041549 · doc4.xml · nonDerivative · entry 3 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:13 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $106.47 | $0.00 |
DisclosureSEC source: 0001209191-20-041549 · doc4.xml · derivative · entry 5 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2030-07-01 F5 · derivative.exercise_date: Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:13 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,057 | $106.47 | $112,538.79 |
DisclosureSEC source: 0001209191-20-041549 · doc4.xml · nonDerivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,591 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:13 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041549 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,648 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Dashyant Dhanak's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:34 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 961 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-20-035524 · doc4.xml · derivative · entry 3 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,525 Underlying: Common Stock · 961 shares Expires 2028-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on December 10, 2019 and the remainder vesting monthly over three years. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:34 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 961 | $91.87 | $88,287.07 |
DisclosureSEC source: 0001209191-20-035524 · doc4.xml · nonDerivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,987 F2 · balance_after: This includes an aggregate of 18,801 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:34 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 961 | $65.42 | $62,868.62 |
DisclosureSEC source: 0001209191-20-035524 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:53 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 961 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-20-027959 · doc4.xml · derivative · entry 3 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,486 Underlying: Common Stock · 961 shares Expires 2028-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on December 10, 2019 and the remainder vesting monthly over three years. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:53 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 961 | $96.84 | $93,063.24 |
DisclosureSEC source: 0001209191-20-027959 · doc4.xml · nonDerivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,987 F2 · balance_after: This includes an aggregate of 18,801 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:53 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 961 | $65.42 | $62,868.62 |
DisclosureSEC source: 0001209191-20-027959 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:35 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,844 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-20-023920 · doc4.xml · derivative · entry 3 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,447 Underlying: Common Stock · 3,844 shares Expires 2028-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on December 10, 2019 and the remainder vesting monthly over three years. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:35 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 3,844 | $85.00 | $326,740.00 |
DisclosureSEC source: 0001209191-20-023920 · doc4.xml · nonDerivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,987 F2 · balance_after: This includes an aggregate of 18,801 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:35 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 3,844 | $65.42 | $251,474.48 |
DisclosureSEC source: 0001209191-20-023920 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010034 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,987 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 13, 2020. The performance shares vest 25% annually over four years from the grant date of July 2, 2019, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded, and the performance criteria was achieved at the 101.80% level. F2 · balance_after: Including the Performance Stock Units earned on February 13, 2020, this includes an aggregate of 18,801 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:11 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004448 · doc4.xml · derivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 21:36 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 533 | $95.72 | $51,018.76 |
DisclosureSEC source: 0001209191-19-060228 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,106 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 11,920 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:31 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040882 · doc4.xml · derivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F3 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:31 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040882 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,639 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Dashyant Dhanak's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 13,639 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 48,403 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-18-062223 · doc4.xml · derivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,403 Underlying: Common Stock · 48,403 shares Expires 2028-12-10 F2 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-062223 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,878 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Dr. Dashyant Dhanak's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.